Devonian Health Group Inc. will take part in Three Renmark’s no-deal virtual Roadshow series

QUEBEC CITY-(BUSINESS WIRE)–Devonian Health Group Inc. (“Devonian” or “corporation“) (TSXv: GSD; OTCQB: DVHGF), a clinical-stage botanical pharmaceutical corporation focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, announced today that they will be participating in three Renmark Financial Communications live non-dealing virtual series to discuss the latest investor presentation.

Full Roadshow Series Event Schedule:

New York, USA: Tuesday, October 25 at 10:00 a.m. EDT

Boston, USA: Thursday, November 10 at 12:00 PM EDT

Toronto, Canada: Thursday, December 8 at 12pm EDT.

The presentation will include President and CEO Pierre Montanaro and Chief Scientific Officer Dr. Andre P. Boule. Topics to be covered will include the latest corporate investor presentation followed by a live Q&A. Investors interested in participating in this event will need to register via the link below. As a reminder, registration for the live event may be limited, but access to the post-event replay will be on the company’s investor page (

Devonian welcomes stakeholders, investors and other individual followers to register and attend this live event.


new York Tuesday, October 25, 2022:

BostonThursday, November 10, 2022:

TorontoThursday, December 8, 2022:

To ensure a smooth connection, please open this link with the latest version of Google Chrome.

About Devon

Devonian Health Group Inc. (Devonian) is a late-stage botanical pharmaceutical corporation with novel therapeutic approaches to target unmet medical needs. Devonian’s core strategy is to develop prescription botanical medicines from plant materials and algae for the treatment of inflammatory autoimmune diseases, including but not limited to ulcerative colitis and atopic dermatitis. Based on a foundation of over 15 years of research, Devonian’s focus is further supported by a set of US-FDA regulatory guidelines favoring a more efficient drug development pathway for prescription botanicals compared to traditional drugs , available with a prescription. Devonian’s flagship product, Thykamine™, the first pharmaceutical product released from Devonian’s SUPREX™ platform, is a highly innovative product for the prevention and treatment of health conditions related to inflammation and oxidative stress. The anti-inflammatory, antioxidant and immunomodulatory properties of Thykamine™ have been demonstrated in a significant number of in vitro and in vivo studies, as well as in a phase IIa clinical trial in patients with mild to moderate distal ulcerative colitis and in a large phase 2 clinical trial in adult patients with mild to moderate atopic dermatitis.

Devonian is also involved in the development of high quality cosmeceutical products using the same proprietary approach used with their pharmaceutical offerings. Devonian Health Group Inc. was incorporated in 2015 and is headquartered in Quebec, Canada, where it has a state-of-the-art extraction facility with full traceability from seed to pill. Acquired in 2018, Altius Healthcare Inc., its commercialization subsidiary, brings opportunities for further diversification and growth potential. Devonian is listed on the TSX Venture Exchange (TSXV: GSD), as well as the OTCQB Venture Exchange (OTCQB:DVHGF)

For more information, visit

About Renmark Financial Communications Inc.

Founded in 1999, Renmark Financial Communications Inc. is the leading retail investor relations firm in North America. Using a strategic and comprehensive mix of exposure tactics; Renmark hosts trade-free virtual demos as well as in-person corporate presentations and maintains daily communication with thousands of brokers and money managers in Canada and the United States. Renmark enables its publicly traded clients to maximize their visibility in the financial community and strengthen their investor audience.

Leave a Comment

Your email address will not be published. Required fields are marked *